share_log

Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis

Sanofi | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

赛诺菲安万特 | 6-K:外国发行人报告
SEC announcement ·  03/20 14:13
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息